Cellectar Biosciences stock soars after FDA grants rare pediatric designation By Investing.com
Update: 2025-10-27
Description
Hope for kids with brain cancer? Cellectar Biosciences stock skyrockets 27% after FDA grants Rare Pediatric Disease Designation to its iopofosine I-131 therapy. Promising trial data shows significantly longer survival rates in children with aggressive brain tumors, paving the way for potential breakthrough treatment. Will this be the game-changer families desperately need?
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel




